Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors associated with hospitalizations for Covid-19 in patients with rheumatoid arthritis: data from the Reumacov Brazil registry.
Gomides APM, de Albuquerque CP, da Mota LMH, Devidé G, Dias LH, Duarte ALBP, Giovelli RA, Karnopp TE, de Lima HD, Marinho A, de Oliveira MS, Omura F, Ranzolin A, Resende G, Ribeiro FM, Ribeiro SLE, de Carvalho Sacilotto N, Dos Santos WG, Shinjo SK, de Sousa Studart SA, Teixeira FPS, Yazbek MA, Ferreira GA, Monticielo OA, Paiva E, Pileggi GCS, Dos Reis-Neto ET, de Medeiros Pinheiro M, Marques CDL; ReumaCoV Brasil Registry. Gomides APM, et al. Among authors: de lima hd. Adv Rheumatol. 2022 May 3;62(1):13. doi: 10.1186/s42358-022-00244-5. Adv Rheumatol. 2022. PMID: 35505408 Free PMC article.
Treatment with biological therapy is associated with faster recovery and lower frequency of treatment switch among rheumatic patients with Chikungunya fever.
Ranzolin A, Marques CDL, da Rocha Junior LF, Duarte ALBP, de Lima HD, de Almeida Martins LM, de Almeida AR, de Oliveira PSS, de Melo Rêgo MJB, da Rocha Pitta MG, Bredemeier M, Laurindo IMM. Ranzolin A, et al. Among authors: de lima hd. Adv Rheumatol. 2022 Nov 14;62(1):44. doi: 10.1186/s42358-022-00273-0. Adv Rheumatol. 2022. PMID: 36376923
The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis.
Bredemeier M, Duarte ÂL, Pinheiro MM, Kahlow BS, Macieira JC, Ranza R, Miranda JR, Valim V, de Castro GR, Bértolo MB, Sauma MF, Fernandes V, Ribeiro AC, Teodoro RB, Brenol CV, Carvalho HM, Studart SA, Pinheiro GR, da Rocha LF Jr, de Lima HD, Pereira IA, Gazzeta MO, Kakehasi AM, Louzada P Jr, Hayata AL, Lupo CM, da Silveira IG, Kowalski SC, Titton DC, Chakr RM, Ranzolin A, Xavier RM, Laurindo IM. Bredemeier M, et al. Among authors: de lima hd. Rheumatology (Oxford). 2024 Feb 1;63(2):456-465. doi: 10.1093/rheumatology/kead232. Rheumatology (Oxford). 2024. PMID: 37216912
Sensitivity and specificity of Interleukin 29 in patients with rheumatoid arthritis and other rheumatic diseases.
da Rocha Junior LF, Branco Pinto Duarte AL, de Melo Rêgo MJB, de Almeida AR, de Melo Vilar K, de Lima HD, Tavares Dantas A, de Ataíde Mariz H, da Rocha Pitta I, da Rocha Pitta MG. da Rocha Junior LF, et al. Among authors: de lima hd. Immunol Lett. 2020 Apr;220:38-43. doi: 10.1016/j.imlet.2020.01.004. Epub 2020 Jan 16. Immunol Lett. 2020. PMID: 31954799